Kilo.

Kilo.

← Back to Blog

GLP-1 Receptor Agonists: Semaglutide & Tirzepatide

⚠ Research Use Disclaimer

For informational and educational purposes only. BPC-157 is for in-vitro research use only. Not for human or animal use. Not medical advice.

The Rise of GLP-1 Agonists in Research

GLP-1 receptor agonists have become some of the most heavily studied compounds in metabolic biology research. Semaglutide, a GLP-1 receptor agonist, and Tirzepatide, a dual GIP/GLP-1 receptor agonist, represent two of the most prominent research compounds in this class.

Semaglutide in Research

Semaglutide is a GLP-1 receptor agonist with approximately 94% homology to native GLP-1. Its enhanced half-life compared to native GLP-1 makes it particularly interesting for research applications requiring sustained receptor engagement studies.

Tirzepatide: Dual Agonism

Tirzepatide’s dual mechanism — acting on both GLP-1 and GIP receptors — has made it the subject of considerable research interest, particularly in metabolic biology studies examining the combined effects of these two incretin pathways.

Kilo.

Follow Us
Linkedin X-twitter Icon-instagram-1 Facebook-square
Research — Kiloresearch.com

Research Use Verification Required

⚠ Important Notice

All products sold on kiloresearch.com are strictly for laboratory and research use only. NOT for human or animal consumption, self-administration, or any therapeutic purpose.

Products are intended solely for scientific investigation by qualified professionals. Not approved by the FDA for human use.

By accessing this website, you confirm that you understand and accept all associated risks, and that you are purchasing solely for lawful research purposes.

Kilo Research bears no liability for misuse of its products.
By entering you confirm you have read and agreed to all terms above.